drugset / Trial / NCT04328844
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
Non-randomizedSequentialOpen-labelTreatment
Summary
The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)
Timeline
- Start
- 2020-02-25
- Primary completion
- 2023-12-13
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | roginolisib | Small molecule | — | Oral |
| Background | Avelumab | Monoclonal antibody | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | Intravenous |
| Background | Ruxolitinib | Small molecule | — | Oral |